Erasca, Inc. $ERAS Shares Bought by Rock Springs Capital Management LP

Rock Springs Capital Management LP lifted its position in Erasca, Inc. (NASDAQ:ERAS) by 15.9% during the first quarter, Holdings Channel reports. The institutional investor owned 1,103,469 shares of the company’s stock after buying an additional 151,759 shares during the quarter. Rock Springs Capital Management LP’s holdings in Erasca were worth $17,854,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. KBC Group NV bought a new position in Erasca during the first quarter valued at about $81,000. State of Wyoming bought a new stake in Erasca in the first quarter worth about $95,000. EntryPoint Capital LLC bought a new stake in Erasca in the fourth quarter worth about $38,000. Stifel Financial Corp acquired a new stake in Erasca in the 4th quarter valued at about $38,000. Finally, XTX Topco Ltd acquired a new stake in Erasca in the 4th quarter valued at about $40,000. Institutional investors and hedge funds own 67.78% of the company’s stock.

Erasca News Summary

Here are the key news stories impacting Erasca this week:

• Neutral Sentiment: Investors who purchased Erasca securities between January 14, 2025, and April 26, 2026, have until August 10, 2026, to seek appointment as lead plaintiff. The deadline is procedural and does not determine the lawsuit’s merits. Kaplan Fox Erasca investor notice
• Negative Sentiment: A securities class action alleges that Erasca and certain executives misled investors about ERAS-0015’s competitive performance, safety profile and intellectual-property protection. Law firms cited the company’s prior claims that the drug could match a leading competitor at one-tenth the dose, had no patentability roadblocks and could be protected through 2043, followed by April disclosures of patent-infringement allegations and an admission that the comparisons were not based on head-to-head trials. Levi and Korsinsky Erasca shareholder alert
• Negative Sentiment: A large number of law firms—including Rosen, Kaplan Fox, Kahn Swick & Foti, Robbins, Hagens Berman and others—are soliciting affected investors and publicizing the case. The repeated notices increase visibility of potential litigation costs, management distraction and uncertainty surrounding Erasca’s clinical and commercial prospects, although the allegations have not been proven in court. Hagens Berman Erasca investor deadline

Erasca Trading Down 1.3%

Shares of ERAS opened at $18.87 on Tuesday. The business’s 50-day moving average price is $15.61 and its 200 day moving average price is $14.10. The stock has a market capitalization of $5.87 billion, a P/E ratio of -20.29 and a beta of 0.66. Erasca, Inc. has a 1-year low of $1.33 and a 1-year high of $24.28.

Erasca (NASDAQ:ERAS) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.48). On average, research analysts predict that Erasca, Inc. will post -0.54 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ERAS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Erasca in a research note on Thursday, June 11th. Wolfe Research set a $16.00 target price on shares of Erasca in a report on Thursday, June 4th. Morgan Stanley increased their target price on shares of Erasca from $12.00 to $21.00 and gave the company an “equal weight” rating in a research note on Monday, July 20th. HC Wainwright restated a “buy” rating on shares of Erasca in a report on Tuesday, July 14th. Finally, Jefferies Financial Group restated a “buy” rating on shares of Erasca in a research report on Tuesday, July 14th. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $21.64.

Erasca Company Profile

Erasca, Inc is a clinical?stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene?driven and immuno?oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.